drugset / Trial / NCT01550185
Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out the highest safe dose and examine the side effects and effectiveness of eltrombopag olamine in patients with acute myeloid leukemia (AML) treated with chemotherapy that have not responded to previous therapy or have suffered a relapse
Timeline
- Start
- 2012-05
- Primary completion
- 2014-12
- Completion
- 2014-12
Outcome
Outcome not reported
Stopped: “Sponsor wanted study rewritten”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SB-497115-GR | Unknown | — | Oral |
Indications
acute basophilic leukemia
acute erythroid leukemia
acute megakaryoblastic leukemia in adult
acute myeloblastic leukemia with maturation
acute myeloblastic leukemia without maturation
acute myeloid leukemia with 11q23 abnormalities
acute myeloid leukemia with minimal differentiation
acute myeloid leukemia with t(8;21)(q22;q22) translocation
acute myeloid leukemia, del(5q31-q32)
acute myeloid leukemia, inv(16)(p13.1;q22)
acute myeloid leukemia, t(16;16)(p13.1;q22)
acute myelomonocytic leukemia M4
adult acute monocytic leukemia